Cargando…
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
INTRODUCTION: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and complex. Clear guidelines for analyses of these resistance mechanisms are currently lacking. Here, we provide our recommendati...
Autores principales: | Hondelink, Liesbeth M., Jebbink, Merel, von der Thüsen, Jan H., Cohen, Danielle, Dubbink, Hendrikus J., Paats, Marthe S., Dingemans, Anne-Marie C., de Langen, Adrianus J., Boelens, Mirjam C., Smit, Egbert F., Postmus, Pieter E., van Wezel, Tom, Monkhorst, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608608/ https://www.ncbi.nlm.nih.gov/pubmed/34849493 http://dx.doi.org/10.1016/j.jtocrr.2021.100252 |
Ejemplares similares
-
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018) -
Development and validation of a supervised deep learning algorithm for automated whole‐slide programmed death‐ligand 1 tumour proportion score assessment in non‐small cell lung cancer
por: Hondelink, Liesbeth M, et al.
Publicado: (2021) -
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
por: Steendam, Christi M. J., et al.
Publicado: (2020) -
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020) -
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
por: Borm, Frank J., et al.
Publicado: (2023)